Substantial doubt about the company's ability to continue as a going concern.
“Because of historical and expected operating losses and net operating cash flow deficits, there is substantial doubt about the Company's ability to continue as a going concern for one year from the issuance of the financial statements, which is not alleviated by management's plans.”View the 10-Q filed Aug 11, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Dermata Therapeutics, Inc. announced the first participant enrolled in a clinical trial evaluating Tome Clearing Treatment, its once-weekly acne treatment, and expects to launch this second commercial product in the first half of 2027.
Dermata Therapeutics registered up to 6,919,560 common shares for resale by selling stockholders, including shares issuable upon warrant exercises; cash exercise proceeds are earmarked for working capital and general corporate purposes.
